Targeting the BCR–ABL tyrosine kinase in chronic myeloid leukemia as a model of rational drug design in cancer

References

• Faderl S, Talpaz M, Estrov Z, O’Brien S, Kurzrock R, Kantarjian HM. The biology of chronic myeloid leukemia. N. Eng. J. Med.341, 164–172 (1999).
   PubMed Web of Science ®Google Scholar
• Melo JV, Barnes DJ. Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nat. Rev. Cancer7, 441–453 (2007).
   PubMed Web of Science ®Google Scholar
• Savage DG, Szydlo RM, Goldman JM. Clinical features at diagnosis in 430 patients with chronic myeloid leukemia seen at a referral center over a 16-year period. Br. J. Haematol.96, 111–116 (1997).
   PubMed Web of Science ®Google Scholar
• Radich JP. The biology of CML blast crisis. Hematology1, 384–391 (2007).
   Google Scholar
• Rowley JD. A new consistent abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and giemsa staining. Nature243, 290–293 (1973).
   PubMed Web of Science ®Google Scholar
• Nowell PC, Hungerford DA. A minute chromosome in human granulocytic leukemia. Science132, 1497 (1960).
   Web of Science ®Google Scholar
• Goldman JM, Melo JV. Chronic myeloid leukemia – advances in biology and new approaches to treatment. N. Engl. J. Med.349, 1451–1464 (2003).
   PubMed Web of Science ®Google Scholar
• Melo JV. The diversity of BCR–ABL fusion proteins and their relationship to leukemia phenotype. Blood88, 2375–2384 (1996).
   PubMed Web of Science ®Google Scholar
• Deininger MWN, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukaemia. Blood96, 3343–3356 (2000).
   PubMed Web of Science ®Google Scholar
• Bruno C, Danilo P. The biology of CML blast crisis. Blood103, 4010–4022 (2004).
   PubMed Web of Science ®Google Scholar
• Quintás-Cardama A, Cortes J. Molecular biology of bcr–abl1-positive chronic myeloid leukemia. Blood113, 1619–1630 (2009).
   PubMed Web of Science ®Google Scholar
• Druker BJ. Translation of the Philadelphia chromosome into therapy for CML. Blood112, 4808–4817 (2008).
   PubMed Web of Science ®Google Scholar
• Geary CG. The story of chronic myeloid leukaemia. Br. J. Haematol.10, 2–11 (2000).
   Google Scholar
• Gratwohl A, Brand R, Apperley J et al. Allogeneic hematopoietic stem cell transplant for chronic myeloid leukemia in Europe 2006: transplant activity, long-term data and current results: an analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Haematologica91, 513–521 (2006).
   PubMed Web of Science ®Google Scholar
• Deininger M, Buchdunger E, Druker BJ. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood105, 2640–2653 (2005).
   PubMed Web of Science ®Google Scholar
• Okabe M, Uehara Y, Miyagishima T et al. Effect of herbimycin A, an antagonist of tyrosine kinase, on bcr/abl oncoprotein-associated cell proliferations: abrogative effect on the transformation of murine hematopoietic cells by transfection of a retroviral vector expressing oncoprotein P210bcr/abl and preferential inhibition on Ph1-positive leukemia cell growth. Blood80, 330–1338 (1992).
   Google Scholar
• Anafi M, Gazit A, Zehavi A, Ben Neriah Y, Levitzki A. Tyrphostin-induced inhibition of p210bcr–abl tyrosine kinase activity induces K562 to differentiate. Blood82, 3524–3529 (1993).
   PubMed Web of Science ®Google Scholar
• Buchdunger E, Zimmermann J, Mett H et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res.56, 100–104 (1996).
   PubMed Web of Science ®Google Scholar
• Carroll M, Ohno Jones S, Tamura S et al. CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR–ABL, TEL–ABL, and TEL–PDGFR fusion proteins. Blood90, 4947–4952 (1997).
   PubMed Web of Science ®Google Scholar
• Jabbour E, Cortes JE, Ghanem H, O’Brien S, Kantarjian HM. Targeted therapy in chronic myeloid leukemia. Expert Rev. Anticancer Ther.8(1), 99–110 (2008).
   PubMed Web of Science ®Google Scholar
• Druker BJ, Talpaz M, Resta DJ et al. Efficacy and safety of a specific inhibitor of the BCR–ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med.344, 1031–1037 (2001).
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Sawyers C, Hochhaus A et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N. Engl. J. Med.346, 645–652 (2002).
   PubMed Web of Science ®Google Scholar
• Talpaz M, Silver RT, Druker BJ et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a Phase 2 study. Blood99, 1928–1937 (2002).
   PubMed Web of Science ®Google Scholar
• Sawyers CL, Hochhaus A, Feldman E et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myeloid leukemia in myeloid blast crisis: results of a Phase II study. Blood99, 3530–3539 (2002).
   PubMed Web of Science ®Google Scholar
• Druker BJ, Guilhot F, O’Brien SG et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N. Engl. J. Med.355, 2408–2417 (2006).
   PubMed Web of Science ®Google Scholar
• Palandri F, Castagnetti F, Alimena G et al. The long-term durability of cytogenetic responses in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: the GIMEMA CML Working Party experience after a 7-year follow-up. Haematologica94, 205–212 (2009).
   PubMed Web of Science ®Google Scholar
• Noens L, van Lierde MA, De Bock R et al. Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood113, 5401–5411 (2009).
   PubMed Web of Science ®Google Scholar
• Larson RA, Druker BJ, Guilhot F et al. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood111, 4022–4028 (2008).
   PubMed Web of Science ®Google Scholar
• Shah NP. Loss of response to imatinib: mechanisms and management. Hematology183–187 (2005).
   PubMed Web of Science ®Google Scholar
• Gorre ME, Mohammed M, Ellwood K et al. Clinical resistance to STI-571 cancer therapy caused by BCR–ABL gene mutation or amplification. Science293, 876–880 (2001).
   PubMed Web of Science ®Google Scholar
• Branford S, Rudzki Z, Walsh S et al. High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood99, 3472–3475 (2002).
   PubMed Web of Science ®Google Scholar
• Hochhaus A, Kreil S, Corbin AS et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia16, 2190–2196 (2002).
   PubMed Web of Science ®Google Scholar
• Branford S, Rudzki Z, Walsh S et al. Detection of BCR–ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood102, 276–283 (2003).
   PubMed Web of Science ®Google Scholar
• Ernst T, Erben P, Muller MC et al. Dynamics of BCR–ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib. Haematologica93, 186–192 (2008).
   PubMed Web of Science ®Google Scholar
• Martinell GI, Soverini S, Iacobucci I. What we don’t know about resistance to tyrosine kinase inhibitors in CML: what makes CML cells a tougher enemy than expected? Clin. Leukemia2, 86–87 (2008).
   Google Scholar
• Koptyra M, Falinski R, Nowicki MO et al.BCR/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance. Blood108, 319–327 (2006).
   PubMed Web of Science ®Google Scholar
• Jiang X, Saw KM, Eaves A, Eaves C. Instability of BCR–ABL gene in primary and cultured chronic myeloid leukemia stem cells. J. Natl Cancer Inst.99, 680–693 (2007).
   PubMed Web of Science ®Google Scholar
• Stoklosa T, Poplawski T, Koptyra M et al.BCR/ABL inhibits mismatch repair to protect from apoptosis and induce point mutations. Cancer Res.68, 2576–2580 (2008).
   PubMed Web of Science ®Google Scholar
• Margret S, Rodrigues, Martin S. Chronic myelogenous leukemia progenitors display a genetically unstable personality. J. Natl Cancer Inst.99, 662–663.
   PubMedGoogle Scholar
• Thomas J, Wang L, Clark RE, Pirmohamed M. Active transport of imatinib into and out of cells: implications for drug resistance. Blood104, 3739–3745 (2004).
   PubMed Web of Science ®Google Scholar
• White DL, Saunders VA, Dang P et al. Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity. Blood110, 4064–4072 (2007).
   PubMed Web of Science ®Google Scholar
• Hiwase DK, Saunders V, Hewett D et al. Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications. Clin. Cancer Res.14, 3881–3888 (2008).
   PubMed Web of Science ®Google Scholar
• White DL, Saunders VA, Dang P et al. OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. Blood108, 697–704 (2006).
   PubMed Web of Science ®Google Scholar
• Zhang WW, Cortes JE, Yao H et al. Predictors of primary imatinib resistance in chronic myelogenous leukemia are distinct from those in secondary imatinib resistance. J. Clin. Oncol.27, 3642–3649 (2009).
   PubMed Web of Science ®Google Scholar
• Schiffer CA. BCRndash;ABL tyrosine kinase inhibitors for chronic myelogenous Leukemia357, 258–265 (2007).
   Google Scholar
• Kantarjian H, Pasquini R, Hamerschlak N et al. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized Phase 2 trial. Blood109, 5143–5150 (2007).
   PubMed Web of Science ®Google Scholar
• Tokarski JS, Newitt JA, Chang CY et al. The structure of dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. Cancer Res.66, 5790–5797 (2006).
   PubMed Web of Science ®Google Scholar
• O’Hare T, Eide CA, Deininger MW. BCR–ABL kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood110, 2242–2249 (2007).
   PubMed Web of Science ®Google Scholar
• Redaelli S, Piazza R, Rostagno R et al. Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants. J. Clin. Oncol.27, 469–471 (2009).
   PubMed Web of Science ®Google Scholar
• Soverini S, Colarossi S, Gnani A et al. Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR–ABL kinase domain. Haematologica92, 401–404 (2007).
   PubMed Web of Science ®Google Scholar
• Hochhaus A, Kantarjian HM, Baccarani M et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood109, 2303–2309 (2007).
   PubMed Web of Science ®Google Scholar
• Guilhot F, Apperley JF, Kim DW et al. Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. Blood109, 4143–4150 (2007).
   PubMed Web of Science ®Google Scholar
• Apperley JF, Cortes JE, Kim DW et al. Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START A trial. J. Clin. Oncol.27, 3472–3479 (2009).
   PubMed Web of Science ®Google Scholar
• Cortes J, Rousselot P, Kim DW et al. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood109, 3207–3213 (2007).
   PubMed Web of Science ®Google Scholar
• Shah NP, Kantarjian HM, Kim DW et al. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J. Clin. Oncol.26, 3204–3212 (2008).
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Giles F, Gattermann N et al. Nilotinib (formerly AMN107), a highly selective BCR–ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood110, 3540–3546 (2007).
   PubMed Web of Science ®Google Scholar
• le Coutre P, Ottmann OG, Giles F et al. Nilotinib (formerly AMN107), a highly selective BCR–ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia. Blood15, 1834–1839 (2008).
   Google Scholar
• Giles FJ, Larson RA, Kantarjian HM et al. Nilotinib in patients (pts) with Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia in blast crisis (CML-BC) who are resistant or intolerant to imatinib. Blood110, 310a (2007).
   Google Scholar
• Ray A, Cowan-Jacob SW, Manley PW, Mestan J, Griffin JD. Identification of Bcr/Abl point mutations conferring resistance to the Abl kinase inhibitor AMN107 (Nilotinib) by a random mutagenesis study. Blood109, 5011–5015 (2007).
   PubMed Web of Science ®Google Scholar
• Aguilera DG, Tsimberidou AM. Dasatinib in chronic myeloid leukemia: a review. Ther. Clin. Risk Manag.5, 281–289 (2009).
   PubMedGoogle Scholar
• Castagnetti F, Palandri F, Gugliotta G, et al. Thyrosin kinase inhibitors: nilotinib. Hemat. Meeting Rep.2, 22–26 (2008).
   Google Scholar
• Konig H, Holyoake TL, Bhatia R. Effective and selective inhibition of chronic myeloid leukemia primitive hematopoietic progenitors by the dual Src/Abl kinase inhibitor SKI-606. Blood111, 2329–2338 (2008).
   PubMed Web of Science ®Google Scholar
• Gambacorti-Passerini C, Kantarjian HM, Baccarani M et al. Activity and tolerance of bosutinib in patients with AP and BP CML and Ph+ ALL. J. Clin. Oncol.26s, 7049 (2008).
   Google Scholar
• Martinelli G, Iacobucci I, Cilloni D, Giannoulia P, Soverini S, Piccaluga PP. New drugs to overcome mechanisms of resistance in Ph+ leukemia: bosutinib. Hemat. Meeting Reports2, 27–32 (2008).
   Google Scholar
• Bartram CR, de Klein A, Hagemeijer A et al. Translocation of c-abl oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia. Nature306, 277–280 (1983).
   PubMed Web of Science ®Google Scholar
• Ben-Neriah Y, Daley GQ, Mes-Masson AM, Witte ON, Baltimore D. The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene. Science233, 212–214 (1986).
   PubMed Web of Science ®Google Scholar
• Lugo TG, Pendergast AM, Muller AJ, Witte ON. Tyrosine kinase activity and transformation potency of bcr–abl oncogene products. Science247, 1079–1082 (1990).
   PubMed Web of Science ®Google Scholar
• Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science247, 824–830 (1990).
   PubMed Web of Science ®Google Scholar
• Koschmieder S, Gottgens B, Zhang P et al. Inducible chronic phase of myeloid leukemia with expansion of hematopoietic stem cells in a transgenic model of BCR–ABL leukemogenesis. Blood105, 324–334 (2005).
   PubMed Web of Science ®Google Scholar
• Cohen M, Johnson J, Pazdur R. U.S. food and drug administration drug approval summary: conversion of imatinib mesylate (STI571; Gleevec) tablets from accelerated approval to full approval. Clin. Cancer Res.11, 12–19 (2005).
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Talpaz M, O’Brien S et al. Survival benefit with imatinib mesylate versus-interferon α-based regimens in newly diagnosed chronic phase chronic myelogenous leukemia. Blood108, 1835–1840 (2006).
   PubMed Web of Science ®Google Scholar
• Hughes TP, Kaeda J, Branford S et al. Frequency of major molecular responses to imatinib or interferon a plus cytarabine in newly diagnosed chronic myeloid leukemia. N. Engl. J. Med.349, 1423–1432 (2003).
   PubMed Web of Science ®Google Scholar
• Cortes J, O’Brien S, Kantarjian H. Discontinuation of imatinib therapy after achieving a molecular response. Blood104, 2204–2205 (2004).
   PubMed Web of Science ®Google Scholar
• Rousselot P, Huguet F, Rea D et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood109, 58–60 (2007).
   PubMed Web of Science ®Google Scholar
• Mahon FX, Rea D, Guilhot F et al. Persistence of complete molecular remission in chronic myeloid leukemia after imatinib discontinuation: interim analysis of the STIM trial. J. Clin. Oncol.27, 7084 (2009).
   Google Scholar
• Quintás-Cardama A, Kantarjian H, Jones D et al. Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy. Blood113, 6315–6321 (2009).
   PubMed Web of Science ®Google Scholar
• Palandri F, Iacobucci I, Soverini S et al. Treatment of Philadelphia-positive chronic myeloid leukemia with imatinib: importance of a stable molecular response. Clin. Cancer Res.15, 1059–1063 (2009).
   PubMed Web of Science ®Google Scholar